Clinical Observation And Economic Evaluation Of Different Dose Antibiotic Treatment In Helicobacter Pylori

Object： In this study to evaluate the efficacy and safety of a standard‐dose in combination antacid versus smaller dose10‐day triple regimen for the eradication of Helicobacter pylori infection.methods: A total of108consecutive patients with documented infection were enrolled in this open‐label trial. Group A (standard dose) received Lansoprazole(15mg), amoxicillin (1g),and clarithromyclin (500mg), all twice daily for10days. Group B (small dose) received Lansoprazole(15mg),twice daily.amoxicillin (500mg), and clarithromycin (250mg),all three times a day for10days. urea breath tests(UBT) were performed a minimum of4weeks after treatment and a minimum of2weeks off any acid‐suppressive therapy. Compliance and adverse effects were evaluated throughout the treatment period.Results: A total of108patients were enrolled (54women and54men; mean age51.6±12.2years).1. Eradication occurred in45of54patients (83.3%)n the standard‐dose group versus44of54in the small dose group (81.5%),on an intent‐to‐treat (ITT) analysis (P=1.00).On a Per protocol analysis(PP) eradication rates were45of53(84.9%) and44of51(86.3%),respectively (P=1.00).2. The number of patients reporting any adverse effect was significantly higher in the standard‐dose group (62.3vs.18.2%; P<0.05).3. The cost of treatment was significantly less in patients receiving the small dose regimen (327.6￥vs.258.6￥).conclusions:1.A small dose10‐day regimen of Lansoprazole, amoxicillin, and clarithromycin is equally effective. Eradication rates of both regimens are, however, suboptimal compared with accepted standards.2. A small dose10‐day regimen of Lansoprazole, amoxicillin, and clarithromycin is equally effective but better tolerated than its standard‐dose regimen in the treatment of Helicobacter pylori.3.The smaller dose is cheaper than standard‐dose.